Slide 1: Trial Update Presentation
Dimerix(ASX:DXB) a Phase 2 biotech with a scalable, proprietary platform technology Trial Update Presentation March 2019 @ Dimerix
Slide 2: For personal use only
For personal use only • • • • • • •
Slide 3: Value Proposition
Value Proposition Market The current enterprise _ Capitalisation: valuation does not reflect Reel value: $14 million the opportunity value US$545 million Cash(as at 31 Dec 2018): AU$5.3 million Greater Enterprise reduction in Value: proteinuria $87 million compared to peer data Two further Positive
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 5: About Dimerix
About Dimerix (ASX:DXB) Cc (= J Products DMX-200 — high value Phase 2 assets: + Diabetic Kidney Disease + FSGS Receptor-HIT GPCR screening assay Assets wholly owned by Dimerix @w Dimerix O at Patents Unique GPCR screening technology Clear product differentiation Comprehensive protection + DMX-200 pa
Slide 6: Management & Board of Directors
Management & Board of Directors Executive team Non-executive team @w Dimerix
Slide 7: For personal use only
For personal use only • • • • • • • • • • • • • • • • • • • • • † Diabetic Kidney Disease: Challenges, Progress, and Possibilities, American Journal of Nephrology, 2017. [ONLINE Available at https://cjasn.asnjournals.org/content/early/2017/07/12/CJN.11491116 [Accessed 01Oct18]† * US National Diabete
Slide 8: Product pipeline
Product pipeline 2 aR UiCY DEED afte Focal Segmental Glomert ERA her ES ao - 1) (UNpIscLoseD} For personal use only
Slide 9: Partnering strategy
Partnering strategy * Identify partner(s) with the expertise and resources to advance products to market * Build strategic alliances across commercial, clinical and manufacturing areas at the appropriate stage of development Current collaborations Harry Perkins Institute of Medical Research and Univ
Slide 10: Introduction to DMX-200
Introduction to DMX-200 & @ Dimerix
Slide 11: Irbesartan and DMX-200
For personal use only • Irbesartan 300mg - angiotensin receptor blocker (ARB) • Standard of care • FDA (USA) approved for Diabetic Kidney Disease • DMX-200 - CCR2 antagonist • Small molecule • PDMA (Japan) approved for chronic *different indication hepatitis B • Twice daily, capsule administration •
Slide 12: Proposed mechanism of action
Proposed mechanism of action DMX-200 addresses three key mechanisms that causes renal damage and chronic kidney disease 1 hyperfiltration of and hypertension within blood vessels of the glomeruli @ Dimerix neruli Irbesartan blocks cellular receptors responsible for hyperfiltration & glomerular hyper
Slide 13: For personal use only
For personal use only • • • • • • • •
Slide 14: Patient subgroups
For personal use only • • • • Patient subgroups • Diabetic Kidney Disease • IgA nephropathy • Other proteinuria disease
Slide 15: Diabetic sub-group ACR mean reduction
Diabetic sub-group ACR mean reduction (n=10) ¢ In 2001 - Irbesartan studied in a large group of type 2 diabetics ¢ Proteinuria levels reduced by 24% * In 2017 - DXB Phase 2a study: DMX-200 + Irbesartan Proteinuria levels reduced by a further 35.6% in diabetic sub-group Reduction of proteinuria by >3
Slide 16: For personal use only
For personal use only • • • • o o o • • 80% • • 30%
Slide 17: DMX-200
For personal use only • • • DMX-200 # Kidney Health Australia. 2018. Kidney Fast Facts. [ONLINE] Available at http://kidney.org.au/cms_uploads/docs/kidney-health- australia-kidney-fast-facts-fact-sheet.pdf. [Accessed 15 Sep 2018] * Kidney Health Australia. 2018. Diabetic Kidney Disease. [ONLINE] Ava
Slide 18: For personal use only
For personal use only • • • • • • # pre-genericization *2017, IQVIA, (total = 4.05 million -adjusted by 50%) † Avapro prescribing information ** Ionis, Vifor, Epigen deals in 2018
Slide 19: Value driving events
Value driving events ° ° DKD- complete ReceptorHIT Partnering activities a recruitment recruitment technology platform and discussions vg licensing activities ° ° DKD dosing completion Q4CY19 dosing Communicate with FDA, Build potential pipeline opportunities stream Secure a licensing Develop Dimeri
Slide 20: End of Presentation
DIMERIX End of Presentation
Slide 21: For personal use only
For personal use only
Slide 22: For personal use only
For personal use only Ayoub, Zhang, Kelly, See, Johnstone, McCall, Williams, Kelly, Pfleger (2015) PLoS One 10:e0119803